There are 2789 resources available
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
640TiP - Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F
Presenter: Gero Kramer
Session: ePoster Display
641TiP - Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Presenter: Johann de Bono
Session: ePoster Display
642TiP - Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
Presenter: Niven Mehra
Session: ePoster Display
636P - A comparative analysis of prostate cancer short-term recurrence risk forecast performance between 8-gene signature and commercial panels
Presenter: Jinan Guo
Session: ePoster Display
638P - Evaluating the contribution of virtual peer-led support to comprehensive prostate cancer (PCa) care: The AnCan experience
Presenter: Herbert Geller
Session: ePoster Display
761P - Impact of residual disease on outcomes in patients with ovarian cancer: A meta-analysis
Presenter: Dana Chase
Session: ePoster Display